Abstract:Abstract Background The combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has showed advantages over standard ATRA and chemotherapy (CHT) in the treatment of low- and intermediate-risk acute promeylocytic leukemia (APL). However, the first-line therapy of high-risk APL is controversial, particularly concerning ATO and CHT. A phase 4, prospective, randomized, open-label, multicenter trial was conducted in China to see if CHT could be replaced by ATO in patients with low- and intermediate-risk APL, and if CHT could be minimized by ATO in patients with high-risk disease. Methods Patients all received ATRA and ATO for induction therapy, combined with anthracycline for patients at high risk and those at intermediate risk but once the white blood cell count was over 10¡Á109/L during induction. In consolidation phase, patients of low-risk APL randomly received either 2 cycles of ATRA-ATO (experimental group) or 2 cycles of ATRA-CHT (reference group) treatment. Patients of intermediate-risk disease randomly received either 3 cycles of ATRA-ATO (experimental group) or 2 cycles of ATRA-CHT (reference group), whereas patients of high-risk disease were randomized to receive either 2 cycles of ATRA-ATO-anthracycline and 1 cycle of ATRA-ATO (experimental group) treatment or 2 cycles of ATRA-anthracycline-cytarabine and 1 cycle of ATRA-mid dose cytarabine (reference group). Once they achieved molecular remission, patients of low- and intermediate-risk continued with 3 cycles of maintenance therapy including ATRA and ATO, while those of high-risk received 5 cycles of ATRA, ATO and methotrexate (MTX) treatment (Figure 1). Results A total of 794 eligible patients have been enrolled in the trial since Jul 2012 and started the assigned treatment with informed consent (Figure 2). Complete remission was achieved in 771 of 794 (97.1%) patients. Early death occurred in 23 patients (2.9%). The median follow-up was 23 months (range, 0 to 45). A total of 19 patients relapsed. In patients with low-risk APL, the 3-year estimated disease-free survival rate was 100% and 94.1% in the experimental group and the reference group, respectively (P=0.088). In patients with intermediate-risk disease, it was 96.9% vs 97.9% (P=0.651). And in patients with high-risk disease, it was 92.4% vs 93.7% (P=0.897; Figure 3A). Overall survival (Figure 3B) and event-free survival were also of no significant difference between experimental and reference groups with each risk stratification. And the 3-year overall survival for patients with low-, intermediate-, and high-risk APL was 98.6%, 96.2%, and 90.8%, respectively (P=0.022; Figure 3C). Conclusion ATRA and ATO combination with or without CHT as the induction therapy achieved as high remission rate as in Shanghai Regimen, meanwhile the application of CHT to those with hyperleukocytosis during induction therapy might benefit them with reduced occurrence of early death. ATRA-ATO is not inferior to ATRA-CHT in patients with low-risk APL. ATO could replace CHT in post-induction phase in patients with intermediate-risk APL. And CHT could be minimized by adding ATO as a substitute for cytarabine in patients with high-risk disease. (Funded by the National High-tech Research and Development Program [863 Program] of China 2012AA02A505 and others; ClinicalTrials.gov identifier: NCT01987297.) Disclosures No relevant conflicts of interest to declare.

Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia.

High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia.

Long-Term Efficacy Of Low-Dose All-Trans Retinoic Acid Plus Minimal Chemotherapy Induction Followed By The Addition Of Intravenous Arsenic Trioxide Post-Remission Therapy In Newly Diagnosed Acute Promyelocytic Leukaemia

Long-Term Efficacy of Low-Dose All-Trans Retinoic Acid Plus Individually Adapted Chemotherapy Induction Followed by Arsenic Trioxide Based Post-Remission Therapy in Adults with Newly Diagnosed Acute Promyelocytic Leukemia

The Clinical Efficacy of All-Trans Retinoic Acid Plus Arsenic Trioxide in 177 Newly Diagnosed Acute Promyelocytic Leukemia Patients

Improved long-term survival in all Sanz risk patients of newly diagnosed acute promyelocytic leukemia treated with a combination of retinoic acid and arsenic trioxide-based front-line therapy.

Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy

Arsenic Trioxide Replacing or Reducing Chemotherapy in Consolidation Therapy for Acute Promyelocytic Leukemia (APL2012 Trial)

Oral Realgar-Indigo Naturalis Formula Achieved Comparably High Rate Of Remission And Survival To Intravenous Arsenic Trioxide As A Front-Line Treatment In Newly Diagnosed Acute Promyelocytic Leukemia: A Multi-Center Randomized Trial Aplo7

All-Trans Retinoic Acid Plus Arsenic Trioxide Versus All-Trans Retinoic Acid Plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis

Outcomes and Prognostic Factors of First Relapsed Acute Promyelocytic Leukemia Patients Undergoing Salvage Therapy with Intravenous Arsenic Trioxide and Chemotherapy

Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients

Early Application Of Arsenic Trioxide Improved The Clinical Outcomes Of Acute Promyelocytic Leukemia

The Responses of Arsenic Trioxide-Based Therapy in Newly Diagnosed Acute Promyelocytic Leukemia

The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: A meta-analysis

[Efficacy of Arsenic Trioxide Combined with ATRA and Chemotherapy for Relapsed Acute Promyelocytic Leukemia Patients].

Mutations of Epigenetic Modifier Genes As A Poor Prognostic Factor in Acute Promyelocytic Leukemia under Treatment with All-Trans Retinoic Acid and Arsenic Trioxide

Long-Term Follow-Up Confirms the Benefit of All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (as2o3) As Front Line Therapy for Newly Diagnosed Acute Promyelocytic Leukemia (APL).

Expression of PML-RARα is Up-Regulated During ATRA and Arsenics Combined Induction Without Influence on Long-Term Prognosis of Acute Promyelocytic Leukemia.

Retinoic Acid and Arsenic Trioxide with or Without Chemotherapy for Acute Promyelocytie Leukemia with Different Risk Stratifications: A Interim Analysis of China APL 2012 Study

Long-Term Efficacy and Safety of All-Trans Retinoic Acid/Arsenic Trioxide-Based Therapy in Newly Diagnosed Acute Promyelocytic Leukemia